Dasatinib is an oral inhibitor of Bcr-Abl tyrosine-kinase, Src family tyrosine kinases, c-Kit, and ephrin receptors. It is being evaluated for use in numerous cancers, including advanced prostate cancer. Alternative name: BMS-354825, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide. Purity: ≥99% (HPLC). Solubility: Soluble in DMSO (98mg/ml) or ethanol (1mg/ml). Long Term Storage: -20°C.